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Abstract cDNA cloning of glutamate transporter GLT-1 from 
mouse brain and liver has revealed that 5'-ends of the messages 
are different between brain and liver. In addition, one of the 
GLT-1 cDNAs isolated from liver has been found to possess a 3'-
end different from those of the others. Reverse transcription 
polymerase chain reaction (RT-PCR) amplification using 
primers specific for altered 5'-ends has confirmed that brain 
and liver messages possess their own specific 5'-ends. Both of the 
two З'-ends have been demonstrated by RT-PCR to be present 
not only in liver but also in brain, indicating both brain and liver 
GLT-1 possess two types of З'-ends. Although functional 
properties are not changed by the alteration of N-termini and 
C-termini when expressed in Xenopus laevis oocytes, co-
expression of two liver type GLT-1 with different C-termini 
(mGLT-lA and mGLT-lB) has been found to result in the 
increase in Fmax of transport without changing Km. These 
results suggest the tissue specific alternative splicing at 5'-ends of 
GLT-1 messages and the interesting association of spliced 
variants with different C-termini. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Uptake of glutamate into cells through plasma membrane is 
mediated via highly accumulative Na+-coupled transporters 
[1-3]. By now four isoforms of glutamate transporters, 
GLAST, GLT-1, EAAC1 and EAAT4 have been identified 
[2,3]. In the central nervous system, glutamate transporters 
are expressed in both neurons (EAAC1 and EAAT4) and glial 
cells (GLT-1 and GLAST) [2,3]. The glutamate transporters 
in astrocytes in particular play critical roles to keep extracel-
lular glutamate concentration below neurotoxic level to pro-
tect neurons from glutamate excitotoxicity. This idea has been 
confirmed recently by knockout of glutamate transporters 
[4,5]. Consistent with this, the regional loss of GLT-1, a major 
astrocyte glutamate transporter, has been associated with 
pathogenesis of a neurodegenerative disorder amyotrophic lat-
eral sclerosis [6]. 
In peripheral tissues, glutamate transporters are supposed 
to play pivotal roles in epithelial transport of acidic amino 
acids and in cellular nutrition. Although EAAC1 is proposed 
to be an apical membrane transporter in the epithelia of in-
testine and kidney, other isoforms of glutamate transporters 
in peripheral tissues, however, have not been well character-
ized [7-10]. In the course of Northern blot analysis to deter-
mine the distribution of expression of glutamate transporters 
in peripheral tissues, we have found that GLT-1 is expressed 
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in liver with different message size compared to brain. In this 
paper, we report the characterization of the liver GLT-1. 
2. Materials and methods 
A cDNA fragment of rat GLT-1 was obtained by reverse transcrip-
tion polymerase chain reaction (RT-PCR) using synthetic oligonu-
cleotide primers 5'-ATGGCATCAACCGAGGGTG-3' and 5'-
GCTGGATGCTAAAGCCAGC-3' (corresponding to nucleotide 
97-115 and 417-435 of rat GLT-1 cDNA [11], respectively). First 
strand cDNA was synthesized from brain poly(A)+RNA obtained 
from adult Splague Daeley rat using oligo(dT)i2-is (GibcoBRL, 
MD) as a primer and subjected to PCR amplification with Taq 
DNA polymerase described by the manufacturer (Perkin-Elmer). 
The PCR product (~0.3 kb) was labeled with [32P]dCTP (T7Quick 
prime, Pharmacia) and used as a probe for screening cDNA libraries 
[12]. Non-directional cDNA libraries were constructed from poly-
(A)+RNA prepared from brain and liver of male Jcl:ICR mouse using 
Superscript Choice System (GibcoBRL). Random hexamer and 
oligo(dT)i2-i8 were used as primers for first strand syntheses for brain 
and liver, respectively. cDNAs were ligated to λΖίρίοχ ЕсоВЛ arms 
(GibcoBRL). Screening cDNA libraries, isolation of positive plaques 
and in vivo excision were performed as described elsewhere [12]. 
cDNA inserts were subcloned into EcoRI site of pBluescript II SK~ 
(Stratagene, CA) and sequenced in both direction as described [12]. 
For Northern analysis, Poly(A)+RNA was prepared from male 
JchlCR mouse tissues and blotted onto a nitrocellulose filter (3 μg/ 
lane) [12]. The cDNA insert of clone GLB17 was used as a probe 
labeled with 32P. Hybridization and high stringent washing were per-
formed as described [12]. The final stringent washing was in 0.1 XSSC/ 
0.1% SDS at 65°C. 
To determine the tissue distribution of spliced variants, RT-PCR 
was performed using primers unique to each spliced fragment: 5'-
CTCCAGACCGTGCCCGGGAGAGG-3' (sense primer B) designed 
in the 5'-untranslated region of clone GLB17 from brain (correspond-
ing to nucleotide 623-645); 5'-CAGAACTTGGAAGCCAGTGCAC-
3' (sense primer L) designed in the 5'-untranslated region of clone 
GLL3 from liver (corresponding to nucleotide 1-22); 5'-
CACGTTTCCAAGGTTCTTCCTC-3' (antisense primer a) designed 
on C-terminus region of GLB17 (corresponding to nucleotide 2349-
2370); 5'-TAAGGAGTCCAGCATGCACTAT-3' (antisense primer 
b) designed in the 3'-untranslated region of GLL3 (corresponding to 
nucleotide 1716-1737). For the other sets of PCR, spliced fragment 
specific primers, B, L, a and b, were combined with primers common 
to all the spliced variants, antisense primer X: 5'-AGGCTAGA-
CACCTCGTCG-3' (corresponding to nucleotide 1136-1153 of 
GLB17) and sense primer Y: 5'-GTAAGCCTTACAGCCACC-3' 
(corresponding to nucleotide 1938-1955 of GLB17). 
Functional characteristics of proteins encoded by cDNAs were ex-
amined by Xenopus laevis oocytes expression as described [12]. cRNA 
was obtained by in vitro transcription using T7 RNA polymerase 
from cDNAs in pBluescript II SK~ linearized with Spel for GLB17 
and BamHI for GLL1 and GLL3. Twenty-five ng of cRNA was 
injected to each oocyte. In the experiments in which cRNAs from 
GLL1 and GLL3 were co-injected, the total amount of cRNA injected 
was kept constant (25 ng). The uptake of [14C]L-glutamate (New Eng-
land Nuclear) was measured in the standard uptake solution (NaCl 
100 mM, KC1 2 mM, CaCl2 1 mM, MgCl2 1 mM, HEPES 10 mM, 
Tris 5 mM, pH 7.4) containing 0.25 μα/ml of [14C]L-glutamate and 
non-labeled glutamate to make up the concentration indicated. For 
Na+-free uptake solution, NaCl in the standard uptake solution was 
replaced by choline-Cl. The uptake was measured for 30 min and the 
values were expressed as pmol/oocyte/min. The values obtained were 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793 (9 7)01232-5 
N. Utsunomiya-Tate et al.lFEBS Letters 416 (1997) 312-316 313 
expressed as mean ± s.e.m. For each measurement, 7-8 oocytes were 
used. The statistical analysis between groups was determined by Stu-
dent's unpaired i-test. 
3. Results and discussion 
Ten positive clones were isolated from a random-primed 
mouse brain cDNA library by screening 240000 plaques. 5'-
and З'-end sequencing and the comparison of restriction en-
zyme cleavage patterns indicated that all 10 clones were iden-
tical except the extension of their 5'- and З'-ends varied. The 
longest cDNA (GLB17) contained a 2996 bp cDNA insert 
with a single open reading frame from nucleotide 660 to 
2375 encoding a 572-residue protein (designated mGLT-1) 
which exhibited 97% amino acid sequence identity to rat 
GLT-1 [11]. Amino acid sequence of mGLT-1 was identical 
to that of mouse GLT-1 sequence reported by Mukainaka et 
al. [9]. mGLT-1, however, exhibited some difference (98% 
identity at amino acid level) compared with mouse GLT-1 
reported by Sutherland et al. (D (residue 26), G (62), A 
(112) and К (572) of mGLT-1 were replaced by E, R, V 
and EFD, respectively) [13]. 
Northern blot analysis using GLB17 cDNA as a probe 
revealed a long size of signal (11.3 kb) strongly expressed in 
mouse brain (Fig. 1), which is consistent with a rat Northern 
blot result [11]. GLT-1 was originally thought to be specific to 
brain, however, in this study, we found the expression of 
GLT-1 mRNA also in the peripheral tissue such as liver where 
a short band at 2.2 kb was more predominant than the 11.3 
kb message (Fig. 1). 
To understand the nature of the short message found in 
liver, an oligo(dT)-primed mouse liver cDNA library was 
Fig. 1. High stringency Northern blot analysis of GLT-1 in mice. 
32P-labeled GLB17 cDNA was used as a probe. Skel. muscle: skele-
tal muscle. 
GLB17 GGGGCGTTCCCACGCATGGCATCAACAGAGQGTGCCAACAATATGCCC 
(mGLT-1) M A S T E R A N N M P 
GLL1 /GLL3 CAGTGCACTTCTACAGCTGAGAGAATGGTCAJGTGCCAACAATATGCCC 
(mGLT-lA/mGLT-lB) M V S A N N M P 
в 
GLB17/GLL1 GATGAGTGCAAGGTAACTCTGGCGGCCAATGGAAAGTCAGCTGACTGC 
( M G L T - 1 / D E C K V : T L A A N G K S A D C 
MGLT-1 A ) AGTGTTGAGGAAGAACCTTGGAAACGTGAAAAATAATGA 
S V E E E P W K R E K * 
GLL3 GATGAGTGCAAGGTAÌCCTTTCCCATTCCTGGATATCGAGACCTGGA ТА 
(mGLT-lB) D E C K V : P F P F L D I E T C ! 
TGAATAGTGCATGCTGGACTCCTTAAAAAAAAATCAC 
Fig. 2. Comparison of nucleotide sequences corresponding to N-ter-
mini (A) and C-termini (B) of mGLT-1, mGLT-1 A and mGLT-1 В 
which are encoded by cDNA clones GLB17, GLL1 and GLL3, re-
spectively. Deduced amino acid sequences are attached to the nu-
cleotide sequences. The broken lines indicate the predicted points of 
alternative splicing. *: Stop codon. 
screened using the rat GLT-1 cDNA fragment as a probe. 
Five positive clones were isolated by screening 240000 
plaques. All the clones contained the identical 5'-ends except 
their extension varied. Surprisingly, the 5'-ends of liver GLT-1 
cDNAs were, however, different from those of brain GLT-1 
cDNAs, suggesting alternative splicing at the 5'-ends. Because 
this alteration at the 5'-ends involves the putative N-terminus 
of the protein, N-terminus 6 amino acids in brain GLT-1 are 
replaced by 3 amino acids in liver GLT-1 (Fig. 2A). 
З'-Ends of 4 liver cDNAs out of 5 isolated clones were 
identical to each other and also to those of brain GLT-1 
cDNAs except the variety in the sites of poly A tail addition. 
The poly A tail started at the poly adenylation site AATAAA 
at 28 base downstream from the stop codon in one of the liver 
cDNAs (GLL2) and at the poly adenylation signal-like se-
quence AAATAA 195 base downstream from the stop codon 
(GLL1, GLL4 and GLL5). The long GLT-1 message in brain 
is proposed to use the poly adenylation site at further down-
stream. Therefore, the liver mRNAs have shorter 3'-untrans-
lated region compared to brain mRNA, which explains short-
er messages in liver than those found in brain (Fig. 1). One of 
the liver cDNAs GLL3, a 2198 bp cDNA coding for the 558-
residue protein, contained a unique З'-end, which suggests 
alternative splicing occurring at the З'-ends. Because of this 
alteration, C-terminus 22 amino acids encoded by GLB17 
were replaced by 11 amino acids for GLL3 (Fig. 2B). 
In order to determine the tissue specificity of spliced var-
iants, RT-PCR was performed using primers specific for each 
spliced fragment. As is shown in Fig. ЗА, PCR products were 
obtained for brain poly(A)+RNA only when the primer В 
designed on 5'-untranslated region of brain GLT-1 GLB17 
was used as a sense primer. Antisense primers a and b, de-
signed on varied З'-ends (see Fig. 4), both produced amplifi-
cation products, indicating that brain expresses GLT-1 mes-
sages with two types of З'-ends (Fig. 4). In brain, the PCR 
product produced by primer b was fainter than that by primer 
a (Fig. ЗА and C). This is consistent with the fact that the З'-
end on which primer b was designed was not found in 10 
cDNAs isolated from brain. In liver, only primer L produced 
amplification products regardless of З'-end primers used (Fig. 
ЗА), indicating that liver GLT-1 messages contain only liver 
type 5'-end and both of two types of З'-ends (Fig. 4). 
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Fig. 3. RT-PCR using primers specific for GLT-1 variants. A: Sense primers В or L were combined with antisense primers a or b. B: 
primers В or L were combined with an antisense primer X. C: A sense primer Y was combined with antisense primers a or b (see text). 
Sense 
The observations in Fig. ЗА were further confirmed by 
additional RT-PCR in which the spliced fragment specific 
primers were combined with primers common to all the 
spliced variants (Fig. 3B and C). Fig. 3B indicates 'brain 
type 5'-end' amplified with primer В and 'liver type 5'-end' 
amplified with primer L were only found in brain and liver, 
respectively. Both of the З'-ends identified with primer a (des-
ignated as 'type a З'-end') and primer b (designated as 'type b 
З'-end') were found in both brain and liver (Fig. 3C). We now 
name mouse liver GLT-ls encoded by GLL1 (liver type 5'-
end/type a З'-end) and GLL3 (liver type 5'-end/type b 3'-end) 
as mGLT-lA and mGLT-lB, respectively, while mouse brain 
GLT-1 encoded by GLB17 (brain type 5'-end/type a З'-end) is 
mGLT-1. 
In order to address the question whether the variations 
found among N-termini and C-termini of GLT-1 proteins 
affect transport functions, functional properties of mGLT-1, 
mGLT-1 A and mGLT-1 В were compared. When expressed in 
Xenopus laevis oocytes, mGLT-1, mGLT-1 A and mGLT-1 В 
all exhibited Na+-dependent transports of [14C]L-glutamate 
(data not shown). As shown in Fig. 5A, glutamate uptakes 
in the oocytes expressing mGLT-1, mGLT-1 A and mGLT-1 В 
exhibit similar concentration-dependent profiles with Km val-
ues of 28.0 ±2.9, 32.3 ±1.9, 31.5+2.7 and 33.2 ±2.1 μΜ 
(mean ± s.e.m. of 4 separate experiments), respectively, indi-
cating no change in their affinity to glutamate. Glutamate 
uptakes via mGLT-1 В and mGLT-1, furthermore, exhibited 
similar sensitivity to glutamate uptake inhibitors such as 
г/ггео-ß-hydroxyaspartate, dihydrokainate, L-fraws-pyrroli-
dine-2,4-dicarboxylate and serine-O-sulfate (Fig. 5B) [8]. 
These results indicate that variations in N-terminus and C-
terminus by the alternative splicing of GLT-1 do not affect 
the conformation of substrate binding sites. Therefore, it is 
suggested that both the N-terminus and C-terminus ends of 
GLT-1 which are predicted to be located intracellularly do not 
contribute to assemble the substrate binding sites. 
Because spliced variants exhibited no detectable changes in 
their functions, significance of the 5'-end alternative splicing 
of GLT-1 would be in the tissue specific expression of the 
gene. The differences in 5'-ends of GLT-1 messages in brain 
and liver suggest the existence of tissue specific promoters 
upstream of the exons corresponding to tissue specific 5'-
ends as was described in the other genes [14]. In brain 
GLT-1 gene expression is spatially and temporally regulated 
so as to suit the functional requirements [3]. For example, in 
the course of brain development, the dramatic upregulation of 
GLT-1 gene expression at around postnatal day 14 in cerebral 
cortex coincides with the postnatal development of glutamat-
ergic transmission [15,16]. On the other hand, GLT-1 gene 
expression is down-regulated after regional deafferentiation 
and recovers on nerve fiber regeneration [17]. These facts sug-
gest that astrocytes somehow sense glutamatergic transmission 
occurring in neighboring synapses and optimize GLT-1 gene 
expression so as to maintain extracellular glutamate concen-
tration [3]. The brain specific promoter is probably responsi-
ble for the mechanism through which astrocytes respond to 
the surrounding neural activity. The comparison of brain spe-
cific da-regulatory elements and liver specific ones would pro-
vide some clues to such a specialized function of astrocytes. 
The significance of the alternative splicing at the З'-ends is 
not clear because З'-end spliced variants did exhibit neither 
differences in their functions (Fig. 5) nor differential tissue 
distribution (Fig. 3). Recently it was demonstrated that glu-
tamate transporters exist as homomultimers [18]. Although 
different isoforms cannot form multimene complex, it is still 
possible that spliced variants associate with each other. So, we 
tried co-expression of mGLT-1 A and mGLT-1 В which are 
both expressed in liver and possess different C-termini. As 
shown in Fig. 5A, oocytes co-expressed with mGLT-1 A and 
mGLT-1 В exhibited glutamate uptake with no change in Km 
(Km = 33.5 ±2.1 μΜ for mGLT-1 A/mGLT-lB; mean ± s.e.m. 
of 4 separate experiments, see above for comparison) and 
slight yet significant increase in Kmax (_P<0.05) compared 
with oocytes expressed solely with mGLT-1 A and mGLT-1 В 
(Fmax = 2.40 ±0.17, 2.43 ±0.19, 3.41 ± 0.2 pmol/oocyte/min for 
mGLT-lA, mGLT-lB and mGLT-lA/mGLT-lB, respec-
tively; mean ± s.e.m. of 4 separate experiments). When the 
different ratios of mGLT-1 A and mGLT-1 В cRNA (1:1, 
1:2 and 2:1) were co-injected in the same batch of oocytes 
with the total amount of cRNA injected constant, the Kmax 
value was the highest for mGLT-lA/mGLT-lB ratio 1:1 
(^тах = 3.19, 2.72, 2.51, 2.09, 2.27 pmol/oocyte/min for 
mGLT-lA:mGLT-lB = l : l , 1:2, 2:1, solely mGLT-1 A, solely 
Brain type 







/ s t o p 
\ _ 1 _ T Stop 
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Fig. 4. Structures of GLT-1 mRNAs. ATG: start codon, Stop: stop 
codon, arrow head: poly adenylation site. Left: 5'-end, right: З'-
end. Brain type and liver type 5'-ends and type a and type b 3-ends 
are indicated. mGLT-1, mGLT-1 A and mGLT-1 В encoded by 
cDNA clones GLB17, GLL1 and GLL3 have brain type 5'-end7type 
a З'-end, liver type 5'-end/type a З'-end and liver type 5'-end/type b 
З'-end, respectively. 
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Fig. 5. Functional properties of brain and liver GLT-1. A: A representative result on concentration dependence of glutamate uptake via oo-
cytes which express mGLT-1 (clone GLB17: filled square), mGLT-lA (clone GLLl: filled triangle), mGLT-lB (clone GLL3: filled circle) and 
both mGLT-lA and mGLT-lB (GLL1/GLL3 co-expression: open circle) measured in the same batch of oocytes. Km (цМ)/Ктах (pmol/oocyte/ 
min) are 23.2/1.14, 28.6/2.79, 26.5/2.74 and 29.2/3.89 for mGLT-1, mGLT-lA, mGLT-lB and mGLT-lA/mGLT-lB, respectively. Twenty-five 
ng of cRNA was injected into each oocyte for GLB17, GLLl and GLL3 and 12.5 ng of GLLl cRNA plus 12.5 ng of GLL3 cRNA for 
GLL1/GLL3 co-expression. B: Inhibition profiles of glutamate uptakes (10 μΜ) via mGLT-lB (upper) and mGLT-1 (lower) by glutamate up-
take inhibitors (1 mM). -: water-injected control oocytes, THA: г/ггео-ß-hydroxyaspartate, PDC: L-iran.s-pyrrolidine-2,4-dicarboxylate, DHK: 
dihydrokainate and SOS: serine-O-sulfate. The glutamate uptakes were expressed as % of those of control oocytes. Each data point represents 
mean±s.e.m. (и = 7~8). 
mGLT-1 В, respectively). Although the reason for this increase 
in V-тю is not known, it is conceivable that C-terminus, which 
does not affect substrate binding (see above), somehow con-
tributes to the translocation of substrates, which would be 
reflected by the increase in Vmax. Another possibility is that 
the complex of mGLT-lA and mGLT-lB becomes more sta-
bilized than homomultimers composed solely of mGLT-lA or 
mGLT-lB, so that they are able to stay longer in the plasma 
membrane. It is notable that the C-terminus encoded by type 
а З'-end contains many charged residues whereas that en-
coded by type b З'-end is rather hydrophobic. In liver, in 
particular, it is interesting to know whether the spliced var-
iants with different C-termini co-exist on the plasma mem-
brane of single hepatocytes. 
In the present study, we have characterized glutamate trans-
porter GLT-1 messages expressed in liver and indicated the 
alternative splicing at both 5'- and З'-ends. For the next step 
of study, the characterization of the protein of each spliced 
variant with antibodies, in particular, specific for varied C-
termini would be necessary to understand the mechanisms 
of seemingly co-operative properties and physiological and 
pathophysiological roles of GLT-1 spliced variants. 
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